Table 1.
Demographic and clinical information of the patient with myopericarditis after COVID-19 vaccine and controls.
| Patient with myopericarditis after COVID-19 vaccine | |||
|---|---|---|---|
| Sex | Male | ||
| Age (year) | 24 | ||
| COVID-19 vaccination | 1st dose of mRNA-1273 | ||
| Days after vaccination | 2 | ||
| Body temperature (°C) | 36.1 | ||
| Blood pressure (mmHg) | 125/94 | ||
| Heart rate (beats per minute) | 126 | ||
| Oxygen saturation (%) | 98 | ||
| Laboratory values | On admission | 3-month follow-up | Reference range |
| White blood cell count (K/mm3) | 14.3 | 6.57 | 4.5-11.0 |
| Absolute lymphocyte count (K/mm3) | 0.8 | 1.19 | 1.1-4.8 |
| Hemoglobin (g/dL) | 13.8 | 15.7 | 13.9-16.3 |
| Platelets (K/mm3) | 178 | 212 | 150-350 |
| Sodium (mmol/L) | 139 | – | 135-148 |
| Potassium (mmol/L) | 4.3 | – | 3.5-5.1 |
| Creatinine (mg/dL) | 0.8 | – | 0.6-1.3 |
| Urea nitrogen (mg/dL) | 13 | – | 7-22 |
| Aspartate aminotransferase (U/L) | 116 | – | 0-37 |
| Alanine aminotransferase (U/L) | 35 | – | 0-40 |
| Alkaline phosphatase (U/L) | 35 | – | 30-120 |
| Total bilirubin (mg/dL) | 0.3 | – | 0.0-1.2 |
| Troponin I (ng/mL) | 0.47 (peak 46.0) | <0.04 | <0.04 |
| Pro-B-type natriuretic peptide (pg/mL) | 390 | – | 0-125 |
| Erythrocyte sedimentation rate (mm/h) | 21 | – | 1-15 |
| C-reactive protein (mg/dL) | 8.4 | 0.9 | <0.5 |
| Lactate (mmol/L) | 2.3 | – | 0.5-2.0 |
| Healthy controls (n=5) | |||
| Sex | Male | ||
| Age (year) | 31.2 ± 3.6 | ||
| COVID-19 vaccination | 2nd dose of BNT162b2 | ||
| Days after vaccination | >180 | ||
| Vaccine controls (n=5) | |||
| Sex | Male | ||
| Age (year) | 41.1 ± 9.4 | ||
| COVID-19 vaccination | 1st dose of BNT162b2 | ||
| Days after vaccination | 2 ± 1.7 | ||